BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
Rhea-AI Summary
BriaCell (Nasdaq:BCTX) completed manufacturing clinical supplies of Bria-PROS+™, its next-generation, personalized, off-the-shelf cell-based immunotherapy candidate for prostate cancer. A $2 million non-dilutive NCI grant awarded in August 2025 supports manufacturing and planned clinical evaluation.
The company plans a Phase 1/2a prostate cancer trial in the coming months. Preclinical data show activation of adaptive and innate immunity. Bria-PROS+ leverages the Bria-OTS+ platform, which in breast cancer includes a reported durable complete resolution of a lung metastasis in one patient.
Positive
- $2 million non-dilutive NCI grant supports Bria-PROS+ manufacturing and evaluation
- Manufacturing of Bria-PROS+ clinical supplies completed, enabling planned Phase 1/2a trial
- Preclinical data show activation of T cells, dendritic cells, and NK cells
- Bria-PROS+ built on Bria-OTS+ platform with reported durable complete response case
Negative
- Bria-PROS+ remains early-stage with Phase 1/2a trial not yet initiated
News Market Reaction – BCTX
In the May 14 session, BCTX declined 3.11%, reflecting a moderate negative market reaction. Argus tracked a trough of -21.2% from its starting point during tracking. Our momentum scanner triggered 72 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 9.6x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Phase 3 site expansion | Positive | +2.5% | Added Penn Medicine Abramson Cancer Center as site in pivotal Bria-ABC trial. |
| May 12 | Enrollment update | Positive | -1.9% | Reported Bria-ABC Phase 3 enrollment surpassing 230 patients with 315+ screened. |
| May 07 | Phase 3 site expansion | Positive | -1.2% | Added NYU Langone’s Perlmutter Cancer Center as clinical site in Bria-ABC study. |
| May 06 | FDA IND clearance | Positive | +2.0% | Received FDA clearance to initiate Phase 1/2a Bria-BRES+ study in breast cancer. |
| Apr 27 | Conference data | Positive | +3.9% | Announced six metastatic breast cancer data items for ASCO 2026 presentations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical news often led to modest single-day moves, with a mix of positive alignment and occasional sell-the-news reactions.
Over the past weeks, BriaCell has focused on advancing its immunotherapy pipeline, particularly the pivotal Phase 3 Bria‑IMT breast cancer program and off‑the‑shelf platforms. Clinical expansions at major centers and FDA Fast Track designation underscore a strategy around late‑stage development. Today’s Bria‑PROS+ manufacturing completion extends this approach into prostate cancer, following prior FDA clearance for Bria‑BRES+ and multiple ASCO 2026 data presentations announced on Apr 27. Recent price reactions to similar clinical updates have been modest and mixed.
Key Terms
immunotherapy medical
adaptive immunity medical
innate immunity medical
t-cells medical
dendritic cells medical
natural killer (nk) cells medical
off-the-shelf medical
investigational new drug (ind) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer
- Immune stimulating components of Bria-PROS+ enhance anti-tumor responses
- BriaCell has completed manufacturing clinical supplies of Bria-PROS+ and plans to initiate a Phase 1/2a clinical study in prostate cancer in the coming months
PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed manufacturing clinical supplies of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy candidate for prostate cancer.
In August 2025, BriaCell was awarded a
“We are pleased to announce the completion of clinical supply manufacturing for Bria-PROS+, our next generation personalized immunotherapy candidate for prostate cancer,” stated Dr. William V. Williams, BriaCell’s President & CEO. “The design of Bria-PROS+ is intended to support enhanced immune system activation while maintaining a favorable safety profile. We look forward to advancing Bria-PROS+ into the clinic as we seek to develop new treatment options for prostate cancer patients who do not respond to available therapies.”
As reported in BriaCell’s recent AACR preclinical poster presentation, Bria-PROS+ demonstrated activation of both adaptive and innate immunity including activation of naïve (resting) T-cells, dendritic cells and natural killer (NK) cells. BriaCell believes these preclinical findings support further clinical evaluation as a potential immunotherapy for prostate cancer. Bria-PROS+ is based on the same Bria-OTS+ platform as Bria-BRES+, BriaCell’s next generation breast cancer immunotherapy candidate, which recently received FDA clearance of its Investigational New Drug (IND) application.
Bria-PROS+ builds on Bria-Cell’s Bria-OTS clinical program in breast cancer, where the first patient dosed experienced the sustained complete resolution of a lung metastasis. This 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures achieved complete (
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the completion of clinical supply manufacturing for Bria‑PROS+, the planned initiation of a Phase 1/2a clinical study, and expectations regarding the potential clinical benefits of the Bria‑OTS+ platform, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
